{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T19:48:46Z","timestamp":1769456926347,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Einleitung<\/jats:title>\n                <jats:p>Die katheterbezogene Lebensqualit\u00e4t (LQ) bei Nephrostomietr\u00e4gern wurde bisher noch nie systematisch untersucht. Dies sollte nun erstmalig vergleichend mit einer ebenfalls externen Urinableitung, dem suprapubischen Katheter, geschehen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methodik<\/jats:title>\n                <jats:p>Das die katheterbezogene LQ untersuchende Assessment nach Mary Wilde wurde bei Patienten mit perkutaner Nephrostomie (PCN) in lebenslanger Intention und minimaler Liegedauer von 3\u00a0Monaten vorgelegt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Es zeigte sich insgesamt bei 66\u00a0Patienten (davon 42 mit unilateraler PCN) mit einem Punktwert von median\u00a04,0 auf einer Skala von\u00a00\u20135 eine nur moderat eingeschr\u00e4nkte katheterbezogene LQ. Diese wurde insgesamt und in allen Dom\u00e4nen schlechter als bei Patienten mit suprapubischem Katheter (SPK) bewertet, bei denen sich ein Score von\u00a04,3 im Median fand. Signifikant waren die Unterschiede in den Einzelitems \u201eGef\u00fchl der Erniedrigung\u201c, \u201eKonflikte mit \u00e4rztlichem oder pflegerischem Personal\u201c, \u201eAngst vor schmerzhaften Katheterwechseln\u201c, \u201eGef\u00fchl als kranke Person\u201c, \u201eBehinderungen in Aktivit\u00e4ten des t\u00e4glichen Lebens\u201c und \u201eBesorgnis, nicht alles tun zu k\u00f6nnen, was ich mag\u201c. Ebenso ergaben sich bei PCN-Tr\u00e4gern signifikant h\u00e4ufiger Angst vor Katheterlecks und Uringeruch. Die Anzahl der einliegenden PCN und die Grunderkrankung spielten f\u00fcr die Beurteilung der LQ keine Rolle.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Erstmals wurde die katheterassoziierte LQ, die sich bei PCN-Tr\u00e4gern nur moderat eingeschr\u00e4nkt fand, mit einem validierten Assessment quantitativ eingeordnet. Die Angabe der Betroffenen, sich als \u201ekrank\u201c und in der Aus\u00fcbung von Aktivit\u00e4ten des t\u00e4glichen Lebens \u201ebehindert\u201c zu f\u00fchlen und die Angst vor Urinleckagen und schmerzhaften Wechseln sollten Ansporn f\u00fcr eine sorgf\u00e4ltige Indikationsstellung und technisch korrekte Katheterwechsel sein.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00120-021-01745-9","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T13:02:48Z","timestamp":1642078968000},"page":"31-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vergleich der katheterassoziierten Lebensqualit\u00e4t bei externen Harnableitungen: Nephrostomie vs. suprapubischer Katheter","Comparison of catheter-associated quality of life in external urinary diversion: nephrostomy vs. suprapubic catheter"],"prefix":"10.1007","volume":"61","author":[{"given":"A.","family":"Wiedemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Weinhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Linn\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kirschner-Hermanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Moll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Liebald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bannowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wirz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Brammen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-J.","family":"Heppner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"1745_CR1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jama.1955.02950280015005","volume":"157","author":"WE Goodwin","year":"1955","unstructured":"Goodwin\u00a0WE, Casey\u00a0WC, Woolf\u00a0W (1955) Percutaneous trocar (needle) nephrostomy in hydronephrosis. J\u00a0Am Med Assoc 157:891\u2013894","journal-title":"J Am Med Assoc"},{"key":"1745_CR2","first-page":"404","volume":"71","author":"F New","year":"2018","unstructured":"New\u00a0F, Deverill\u00a0S, Somani\u00a0BK (2018) Role of percutaneous nephrostomy in end of life prostate cancer patients: a\u00a0systematic review of the literature. Cent european J Urol 71:404\u2013409","journal-title":"Cent european J Urol"},{"key":"1745_CR3","doi-asserted-by":"publisher","first-page":"e3191","DOI":"10.1590\/1518-8345.3039.3191","volume":"27","author":"LM Fernandez-Cacho","year":"2019","unstructured":"Fernandez-Cacho\u00a0LM, Ayesa-Arriola\u00a0R (2019) Quality of life, pain and anxiety in patients with nephrostomy tubes. Rev Lat Am Enfermagem 27:e3191","journal-title":"Rev Lat Am Enfermagem"},{"key":"1745_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.gaceta.2015.08.007","volume":"29","author":"JM Cabases","year":"2015","unstructured":"Cabases\u00a0JM (2015) The EQ-5D as a\u00a0measure of health outcomes. Gac Sanit 29:401\u2013403","journal-title":"Gac Sanit"},{"key":"1745_CR5","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00270-013-0571-9","volume":"36","author":"WL Monsky","year":"2013","unstructured":"Monsky\u00a0WL, Molloy\u00a0C, Jin\u00a0B, Nolan\u00a0T, Fernando\u00a0D et al (2013) Quality-of-life assessment after palliative interventions to manage malignant ureteral obstruction. Cardiovasc Intervent Radiol 36:1355\u20131363","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1745_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/21681805.2014.938694","volume":"49","author":"LH Bigum","year":"2015","unstructured":"Bigum\u00a0LH, Spielmann\u00a0ME, Juhl\u00a0G, Rasmussen\u00a0A (2015) A qualitative study exploring male cancer patients\u2019 experiences with percutaneous nephrostomy. Scand J Urol 49:162\u2013168","journal-title":"Scand J Urol"},{"key":"1745_CR7","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/nau.20865","volume":"29","author":"MH Wilde","year":"2010","unstructured":"Wilde\u00a0MH, Getliffe\u00a0K, Brasch\u00a0J, McMahon\u00a0J, Anson\u00a0E, Tu\u00a0X (2010) A new urinary catheter-related quality of life instrument for adults. Neurourol Urodyn 29:1282\u20131285","journal-title":"Neurourol Urodyn"},{"key":"1745_CR8","volume-title":"Expertenstandard F\u00f6rderung der Harnkontinenz in der Pflege","author":"Deutsches Netzwerk f\u00fcr Qualit\u00e4tsentwicklung in der Pflege (DNQP)","year":"2006","unstructured":"Deutsches Netzwerk f\u00fcr Qualit\u00e4tsentwicklung in der Pflege (DNQP) (2006) Expertenstandard F\u00f6rderung der Harnkontinenz in der Pflege. Fachhochschule Osnabr\u00fcck"},{"key":"1745_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0090-4295(98)00454-3","volume":"53","author":"DL Patrick","year":"1999","unstructured":"Patrick\u00a0DL, Martin\u00a0ML, Bushnell\u00a0DM, Yalcin\u00a0I, Wagner\u00a0TH, Buesching\u00a0DP (1999) Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). Urology 53:71\u201376","journal-title":"Urology"},{"key":"1745_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12894-019-0510-4","volume":"19","author":"O Shoshany","year":"2019","unstructured":"Shoshany\u00a0O, Erlich\u00a0T, Golan\u00a0S, Kleinmann\u00a0N, Baniel\u00a0J et al (2019) Ureteric stent versus percutaneous nephrostomy for acute ureteral obstruction\u2014clinical outcome and quality of life: a\u00a0bi-center prospective study. BMC Urol 19:79","journal-title":"BMC Urol"},{"key":"1745_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00240-018-1078-2","volume":"47","author":"N de Sousa Morais","year":"2019","unstructured":"de Sousa Morais\u00a0N, Pereira\u00a0JP, Mota\u00a0P, Carvalho-Dias\u00a0E, Torres\u00a0JN, Lima\u00a0E (2019) Percutaneous nephrostomy vs ureteral stent for hydronephrosis secondary to ureteric calculi: impact on spontaneous stone passage and health-related quality of life\u2014a prospective study. Urolithiasis 47:567\u2013573","journal-title":"Urolithiasis"},{"key":"1745_CR12","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00120-016-0253-8","volume":"55","author":"C Netsch","year":"2016","unstructured":"Netsch\u00a0C, Becker\u00a0B, Gross\u00a0AJ (2016) Management of ureteral obstruction : value of percutaneous nephrostomy and ureteral stents. Urologe\u00a0A 55:1497\u20131510","journal-title":"Urologe A"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01745-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-021-01745-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01745-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T11:04:32Z","timestamp":1642417472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-021-01745-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1745"],"URL":"https:\/\/doi.org\/10.1007\/s00120-021-01745-9","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"24 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Wiedemann gibt Berater- bzw. Gutachtert\u00e4tigkeit f\u00fcr Dr. Pfleger, Pfizer Pharma und Omega Pharma, Mitarbeit in einem Wissenschaftlichen Beirat (advisory board) f\u00fcr Dr. Pfleger, Pfizer Pharma und Omega Pharma, bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit f\u00fcr AMS Deutschland, Astellas, Berlin Chemie, Boston Scientific, Dr. Pfleger, Ipsen, Jansen, Meda, Omega Pharma, Acticor und Aristo, Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien f\u00fcr Boston Scientific, Dr. Pfleger, Paul-Kuth-Stiftung Deutsche Bank sowie folgende indirekte Interessen an: DGU, DGG, DKG und NRW-GU. J.\u00a0Stein gibt Advisory Board der Firma Bayer, bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit f\u00fcr Medac und Lilly, Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien f\u00fcr Medac, Lilly, Jenapharm, Boston Scientific, Pfizer, Takeda, Astellas, Janssen, Sanofi, Dr. Pfleger, Gruenenthal, MSD und Bristol-Myers-Squibb an. C.\u00a0Linn\u00e9 gibt Berater- bzw. Gutachtert\u00e4tigkeit f\u00fcr Apogepha Pharma GmbH, Mitarbeit in einem Wissenschaftlichen Beirat (advisory board) f\u00fcr Apogepha GmbH, Janssen Cilag, MSD, BMS, bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit f\u00fcr MSD, Ratiopharm, Ipsen, Janssen, Apogepha, Pfizer, BMS sowie folgende indirekte Interessen an: DGU. R.\u00a0Kirschner-Hermanns gibt CEO und Founder der MEC\/\/ABC GmbH Medical Care and Product development in Aachen, Bonn und Cologne, bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit f\u00fcr Repha GmbH, Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien Angocei Antinfekt\u00a0N Schulung f\u00fcr Laborie\u202f\u2192\u2009F\u00f6rderverein Kontinenzf\u00f6rderung und Kontinenzaufkl\u00e4rung eV. Aachen, Aktien 100\u202f% Anderl sowie folgende indirekte Interessen an: DAU, DGU, DGG. V.\u00a0Moll gibt Berater- bzw. Gutachtert\u00e4tigkeit f\u00fcr Recordati sowie bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit f\u00fcr Recordati, Aristo und Medac an. J.\u00a0Salem gibt Berater- bzw. Gutachtert\u00e4tigkeit f\u00fcr Lisa Laser, Ambu GmbH, Purenum, bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit f\u00fcr Olympus, Omega Pharma, Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien f\u00fcr Ambu GmbH sowie folgende indirekte Interessen an: DGU, NRW-GU. T.\u00a0Liebald gibt Berater- bzw. Gutachtert\u00e4tigkeit f\u00fcr Apogepha, Sanofi, MSD, Astellas, Mitarbeit in einem Wissenschaftlichen Beirat (advisory board) f\u00fcr Sanofi, MSD, Bayer, Astallas, Roche, Janssen, bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit f\u00fcr Sanofi, Astellas, Janssen, Bayer, MSD, Apogepha, Amgen sowie folgende indirekte Interessen an: DGU. S.\u00a0Wirz gibt Berater- bzw. Gutachtert\u00e4tigkeit f\u00fcr Dr. Pfleger, Stada Pharma, KyowaKirin, Sandoz\/Hexal, Mitarbeit in einem Wissenschaftlichen Beirat (advisory board) f\u00fcr Dr. Pfleger, Stada Pharma, KyowaKirin, Sandoz\/Hexal, bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit f\u00fcr KyowaKirin, Gr\u00fcnenthal, Dr. Kade\/Besin, Mundipharma China an. H.-J.\u00a0Heppner gibt Berater- bzw. Gutachtert\u00e4tigkeit f\u00fcr Astellas Pharma, Pfizer Pharma, bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit f\u00fcr Pfizer Pharma, Bayer Health Care, Mundipharma, Astellas Pharma, MSD, BL\u00c4K, AO Trauma Europa sowie Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien f\u00fcr ThermoScience, Forschungskolleg Geriatrie der Robert-Bosch-Stiftung, Wissenschaftsforum Geriatrie, Infectopharm; GBA Innovationsfonds an. A.\u00a0Schorn, A.\u00a0Wagner und A.\u00a0Bannowsky geben folgende indirekte Interessen an: DGU. M.\u00a0Weinhofer, U.\u00a0Unger und E.\u00a0Brammen geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}